Balyasny Asset Management
SAGE

Balyasny Asset Management’s Sage Therapeutics SAGE Stock Holding History

Balyasny Asset Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,000
Closed -$443K – 2548
2021
Q3 		$443K Buy
+10,000
New +$459K ﹤0.01% 1512
2020
Q4 		– Sell
-150,000
Closed -$9.17M – 1649
2020
Q3 		$9.17M Buy
+150,000
New +$7.6M 0.07% 407
2019
Q1 		– Sell
-160,500
Closed -$15.4M – 1620
2018
Q4 		$15.4M Buy
+160,500
New +$18.4M 0.11% 267
2018
Q2 		– Sell
-80,000
Closed -$12.9M – 2100
2018
Q1 		$12.9M Sell
80,000
-345,000
-81% -$58.6M 0.05% 452
2017
Q4 		$70M Buy
425,000
+245,000
+136% +$23.8M 0.22% 108
2017
Q3 		$11.2M Sell
180,000
-280,000
-61% -$22M 0.04% 468
2017
Q2 		$36.6M Buy
460,000
+435,000
+1,740% +$31.4M 0.15% 180
2017
Q1 		$1.78M Buy
+25,000
New +$1.46M 0.01% 939

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Balyasny Asset Management's SAGE Position: Q3 2025 in Review

Balyasny Asset Management sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 1,518,170 shares — an estimated $13.8M sold.

Balyasny Asset Management first reported a position in SAGE in Q4 2015 and held it in 19 quarters. The position peaked at $43M in Q4 2017. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • Balyasny Asset Management reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 1,518,170 Sage Therapeutics shares in Q3 2025, an estimated $13.8M.
  • Balyasny Asset Management first reported a position in Sage Therapeutics in Q4 2015 and held it in 19 quarters.
  • Balyasny Asset Management's Sage Therapeutics position peaked at $43M in Q4 2017.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Balyasny Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.